DrugCite
Search

NORDITROPIN NORDIFLEX

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Norditropin Nordiflex Adverse Events Reported to the FDA Over Time

How are Norditropin Nordiflex adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Norditropin Nordiflex, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Norditropin Nordiflex is flagged as the suspect drug causing the adverse event.

Most Common Norditropin Nordiflex Adverse Events Reported to the FDA

What are the most common Norditropin Nordiflex adverse events reported to the FDA?

Condition Aggravated
31 (2.73%)
Cardiac Failure Congestive
23 (2.02%)
Headache
23 (2.02%)
Convulsion
19 (1.67%)
Hyperglycaemia
18 (1.58%)
Death
17 (1.5%)
Nausea
17 (1.5%)
Urinary Tract Infection
16 (1.41%)
Vomiting
15 (1.32%)
Blood Glucose Increased
13 (1.14%)
Chest Pain
13 (1.14%)
Show More Show More
Craniopharyngioma
13 (1.14%)
Dehydration
13 (1.14%)
Diarrhoea
13 (1.14%)
Papilloedema
13 (1.14%)
Sleep Apnoea Syndrome
12 (1.06%)
Type 1 Diabetes Mellitus
12 (1.06%)
Arthralgia
11 (.97%)
Scoliosis
11 (.97%)
Atrial Fibrillation
10 (.88%)
Cardiac Failure
10 (.88%)
Gastrointestinal Haemorrhage
10 (.88%)
Migraine
10 (.88%)
Myocardial Infarction
10 (.88%)
Influenza Like Illness
9 (.79%)
Pancreatitis
9 (.79%)
Blood Pressure Increased
8 (.7%)
Cyst
8 (.7%)
Dizziness
8 (.7%)
Pneumonia
8 (.7%)
Pulmonary Oedema
8 (.7%)
Pyrexia
8 (.7%)
Syncope
8 (.7%)
Anxiety
7 (.62%)
Asthenia
7 (.62%)
Atrial Thrombosis
7 (.62%)
Fluid Overload
7 (.62%)
Intracranial Pressure Increased
7 (.62%)
Pituitary Tumour Benign
7 (.62%)
Sepsis
7 (.62%)
Tonsillar Hypertrophy
7 (.62%)
Azotaemia
6 (.53%)
Cough
6 (.53%)
Diabetic Ketoacidosis
6 (.53%)
Eye Haemorrhage
6 (.53%)
Fatigue
6 (.53%)
Haemoptysis
6 (.53%)
Heart Rate Abnormal
6 (.53%)
Hyperthyroidism
6 (.53%)
Loss Of Consciousness
6 (.53%)
Malignant Melanoma
6 (.53%)
Medulloblastoma
6 (.53%)
Protein-losing Gastroenteropathy
6 (.53%)
Retinal Detachment
6 (.53%)
Rhabdomyolysis
6 (.53%)
Stevens-johnson Syndrome
6 (.53%)
Transient Ischaemic Attack
6 (.53%)
Back Pain
5 (.44%)
Bone Cyst
5 (.44%)
Congenital Coronary Artery Malforma...
5 (.44%)
Haemorrhage Intracranial
5 (.44%)
Knee Arthroplasty
5 (.44%)
Osteochondrosis
5 (.44%)
Osteonecrosis
5 (.44%)
Pleural Effusion
5 (.44%)
Shock
5 (.44%)
Thrombosis
5 (.44%)
Upper Respiratory Tract Infection
5 (.44%)
Abdominal Pain
4 (.35%)
Anaemia
4 (.35%)
Angioedema
4 (.35%)
Appendicitis
4 (.35%)
Arthritis Infective
4 (.35%)
Brain Neoplasm
4 (.35%)
Epilepsy
4 (.35%)
Face Oedema
4 (.35%)
Fibrous Dysplasia Of Bone
4 (.35%)
Gastroduodenitis Haemorrhagic
4 (.35%)
Heart Rate Increased
4 (.35%)
Hepatic Enzyme Increased
4 (.35%)
Hypertension
4 (.35%)
Hyponatraemia
4 (.35%)
Influenza
4 (.35%)
Insulin-like Growth Factor Decrease...
4 (.35%)
International Normalised Ratio Abno...
4 (.35%)
Neoplasm
4 (.35%)
Oedema Peripheral
4 (.35%)
Oropharyngeal Pain
4 (.35%)
Pain
4 (.35%)
Pharyngitis Streptococcal
4 (.35%)
Pituitary Tumour
4 (.35%)
Rash Generalised
4 (.35%)
Respiratory Distress
4 (.35%)
Respiratory Failure
4 (.35%)
Swollen Tongue
4 (.35%)
Toothache
4 (.35%)
Transaminases Increased
4 (.35%)
Ventriculoperitoneal Shunt Malfunct...
4 (.35%)
Visual Acuity Reduced
4 (.35%)
Weight Decreased
4 (.35%)
Weight Increased
4 (.35%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Norditropin Nordiflex, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Norditropin Nordiflex is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Norditropin Nordiflex

What are the most common Norditropin Nordiflex adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Norditropin Nordiflex, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Norditropin Nordiflex is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Norditropin Nordiflex According to Those Reporting Adverse Events

Why are people taking Norditropin Nordiflex, according to those reporting adverse events to the FDA?

Growth Hormone Deficiency
181
Haemodialysis
77
Body Height Below Normal
34
Drug Use For Unknown Indication
29
Hypopituitarism
16
Product Used For Unknown Indication
14
Show More Show More
Turners Syndrome
12
Prader-willi Syndrome
12
Small For Dates Baby
11
Chondrodystrophy
9
Growth Retardation
9
Renal Failure Chronic
7
Dwarfism
6
Fatigue
4
Ill-defined Disorder
3
Silver-russell Syndrome
3
Fibromyalgia
3
Blood Growth Hormone Decreased
3
Noonan Syndrome
3
Weight Increased
2
Hepatitis C
2
Short-bowel Syndrome
2
Off Label Use
2
Lymphocytic Hypophysitis
2
Langerhans Cell Granulomatosis
2
Insulin-like Growth Factor Decrease...
2
Gonadal Dysgenesis
2
Hypothalamo-pituitary Disorder
2
Pituitary Tumour Removal
1
Post Procedural Complication
1
Decreased Activity
1
Foetal Growth Retardation
1
Muscle Atrophy
1
Prophylaxis
1
Muscle Disorder
1
Surgery
1
Muscular Weakness
1
Lethargy
1

Norditropin Nordiflex Case Reports

What Norditropin Nordiflex safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Norditropin Nordiflex. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Norditropin Nordiflex.